Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT- GCIG intergroup study (HECTOR)

Jalid Sehouli*, R. Chekerov, A. Reinthaller, R. Richter, A. Gonzalez-Martin, P. Harter, H. Woopen, E. Petru, L. C. Hanker, E. Keil, P. Wimberger, P. Klare, C. Kurzeder, F. Hilpert, A. K. Belau, A. Zeimet, I. Bover-Barcelo, U. Canzler, S. Mahner, W. Meier

*Corresponding author for this work
16 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT- GCIG intergroup study (HECTOR)'. Together they form a unique fingerprint.

Medicine & Life Sciences